Sadat-Sowti B, Debré P, Idziorek T, Guillon J M, Hadida F, Okzenhendler E, Katlama C, Mayaud C, Autran B
Laboratoire d'Immunologie Cellulaire et Tissulaire, CNRS UA 0186, CHU Pitié-Salpétrière, Paris.
Eur J Immunol. 1991 Mar;21(3):737-41. doi: 10.1002/eji.1830210329.
CD8+CD57+ T cells, expanded in peripheral blood lymphocytes of AIDS patients, inhibit the effector phase of HLA-specific cytotoxic T lymphocytes, natural killer and lymphocyte-activated killer cells in a 4-h chromium-release assay. This inhibitory activity present in supernatants of purified sorted CD8+CD57+ cells is mediated by a non-antigen-specific inhibitory factor which is distinct from prostaglandin E2, T cell growth factor (TGF)-beta, latent-TGF-beta, tumor necrosis factor (TNF)-alpha and TNF-beta. Partial biochemical characterization demonstrates that the CD8+CD57+ inhibitory activity (a) is heat, trypsin and acid resistant, (b) binds to concanavalin A columns, indicating its glycosylation state and (c) is mediated by a 20-30-kDa soluble molecule.